Effect of different seat heights on lumbar spine flexion during stand-to-sit motion

[Purpose] This study aimed to investigate the movement of the thorax, lumbar spine, and pelvis when healthy participants sit on a chair, and to identify the kinematic characteristics due to changes in the height of the seat. [Participants and Methods] Twenty healthy participants (14 males, 6 females; mean age, 29 ± 5 years) were recruited for this study. They performed stand-to-sit motion using one seat with a height of 100% that of the lower leg length (standard) and another with a height of 60% that of the lower leg length (lower). A three-dimensional motion analysis system and four force plates were used to analyze each joint angle. [Results] The mean lumbar spine flexion angle was significantly increased in the lower versus the standard seat. As a kinematic characteristic, the pelvis tilted posteriorly while the thorax tilted anteriorly, which increased the lumbar spine flexion angle. The pelvis was tilted posteriorly when the hip joint flexed about 60° regardless of the seat height. [Conclusion] The lumbar spine flexion angle increased in the lower seat stand-to-sit motion, which suggested an increase in the load on the lumbar spine. The lumbar spine flexion angle was influenced by the characteristic movements of the thorax and pelvis.     

Appropriate definition of diabetes using an administrative database: A cross‐sectional cohort validation study

Aims/IntroductionThe purpose of the present study was to quantify errors in the diagnosis of diabetes for use in the national database, using a sufficient population size.Materials and methodsA claims database constructed by the JMDC (Tokyo, Japan), using standardized disease classifications and anonymous record linkage, was used in this validation study. We included patients with health insurance claims data from April 2005 to March 2019 in the JMDC claims database. We excluded patients without a record of specific health checkups in Japan. Sample size calculation was based on a 5% prevalence of diabetes and 0.4% absolute accuracy (i.e., 1,250,000 individuals), to calculate the sensitivity, specificity, positive predictive value and negative predictive value.ResultsIn total, 2,999,152 patients were included in this study, of which 165,515 were classified as having diabetes based on specific health checkups (validation cohort prevalence of 5.5%). The newly devised algorithm had three elements – the diagnosis‐related codes for diabetes without suspected flag, the medication codes for diabetes and then these two codes on the same record – and yielded a sensitivity of 74.6%, positive predictive value of 88.4% and Kappa Index of 0.80 (the highest values).ConclusionsIn future claims database studies, our validated algorithms will be useful as diagnostic criteria for diabetes.     

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus control selected from a total of 99 patients recovered from moderate COVID-19. These subjects participated in the longitudinal (>6 months) analysis of (i) SARS-CoV-2 spike protein’s receptor-binding domain IgG, (ii) virus neutralization assay using authentic virus, and (iii) neutralization potency against original (WT) SARS-CoV-2 and cross-neutralization against B.1.351 (beta) variant carrying triple mutations of K417N, E484K, and N501Y. The results demonstrate that the use of favipiravir: (1) significantly accelerated the elimination of SARS-CoV-2 in the case vs. control groups (p = 0.027), (2) preserved the generation and persistence of neutralizing antibodies in the host, and (3) did not interfere the maturation of neutralizing potency of anti-SARS-CoV-2 and neutralizing breadth against SARS-CoV-2 variants. In conclusion, treatment of COVID-19 with favipiravir accelerates viral clearance and does not interfere the generation or maturation of neutralizing potency against both WT SARS-CoV-2 and its variants.